Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195078 · ClinicalTrials.gov registry record · Phase 1
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00195078 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 29 participants.
The verdict
NCT00195078, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether adding ZD1839 to standard treatment (Cisplatin and Radiation Therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.
Interventions
- DRUG Cisplatin
- PROCEDURE Radiation Therapy
- DRUG ZD1839 (IRESSA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195078
The ClinicalTrials.gov registry entry for NCT00195078 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00195078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195078 about?
NCT00195078 is a clinical study titled "Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer". The purpose of this study is to find out whether adding ZD1839 to standard treatment (Cisplatin and Radiation Therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.
What is the current status of trial NCT00195078?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2004-04. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00195078?
The interventions under investigation include: Cisplatin (DRUG), Radiation Therapy (PROCEDURE), ZD1839 (IRESSA) (DRUG).
Who is sponsoring clinical trial NCT00195078?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.